What is Control4?
Established in 2003 and headquartered in Salt Lake City, UT, Control4 specializes in providing integrated automation and networking solutions for residential and commercial environments. The company offers a personalized smart home system designed to automate and manage connected devices, encompassing lighting, audio, video, climate control, intercom, and security systems. Control4's offerings aim to enhance user experience through seamless control and intelligent automation of everyday environments, positioning it as a leader in the smart technology space.
How much funding has Control4 raised?
Control4 has raised a total of $183.2M across 9 funding rounds:
Series C
$15M
Series D
$20.2M
Series E
$11M
Series F
$20M
Series G
$17.4M
Series H
$15M
Stock Offering
$65.9M
Series C (2005): $15M supported by vSpring Capital, Thomas Weisel Venture Partners, Frazier Healthcare Partners, and Foundation Capital
Series D (2006): $20.2M featuring vSpring Capital, Frazier Healthcare Partners, Foundation Capital, and Thomas Weisel Partners
Series E (2007): $11M backed by vSpring SBIC, Frazier Healthcare Partners, Foundation Capital, and Thomas Weisel Partners
Series F (2008): $20M with participation from Foundation Capital
Series G (2009): $17.5M led by Undisclosed
Series H (2011): $15M supported by vSpring Capital, Thomas Weisel Venture Partners, and Frazier Healthcare Partners
Stock Issuance/Offering (2013): $65.9M featuring Undisclosed
Key Investors in Control4
vSpring Capital
Run Ventures is an investment firm focused on backing early-stage SaaS and technology breakthroughs. The company aims to support innovative startups in the tech sector. Their portfolio includes a range of promising ventures that are poised for growth. Run Ventures is dedicated to helping entrepreneurs succeed in their endeavors.
Frazier Healthcare Partners
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.
Foundation Capital
Foundation Capital is a venture capital firm that partners with bold founders building category-defining technology companies, supporting entrepreneurs from the earliest stages through long-term growth with deep operational and strategic expertise. With a history of backing transformative ideas, the firm focuses on innovation that reshapes industries, guided by a strong belief in conviction, collaboration, and a commitment to lasting impact.
What's next for Control4?
The significant enterprise-level funding Control4 has attracted indicates a strong market position and a clear trajectory for continued innovation and expansion. This sustained investment suggests a strategic focus on scaling operations, enhancing product development, and potentially exploring new market segments or technological advancements in the rapidly evolving smart home and IoT landscape. The company's history of securing diverse rounds of financing points to a robust business model capable of supporting long-term growth and market leadership.
See full Control4 company page
